Owlet Announces First Quarter 2023 Financial Results
See the “Disclosure Regarding Non-GAAP Financial Measures” disclosure and the reconciliation tables that accompany this release for a discussion and reconciliation of certain non-GAAP financial measures included in this release.
Recent Q1 2023 Highlights
-
Generated revenues of
$10.7 million $12 million -
Operational expenses of
$15.1 million 37% from$24.1 million -
Gross margin was
39.3% for the quarter, increasing significantly sequentially from27.5% in Q4 2022. - FDA reviews of the 510(k) submission for the BabySatTM remote pediatric monitoring device, and the de novo submission for the software-as-a-medical-device Health Notifications for use with the Dream Sock, are both on track.
-
In February the Company raised
$30 million - The Company continues to take steps to regain compliance with NYSE listing requirements in a timely manner.
“Our conviction in Owlet’s future remains steadfast as we continue to rebuild our business and position it for profitability later this year. During the quarter, we reduced operating expenses, increased gross margins, and continued to make timely progress on the ongoing regulatory review for both our medical device and de novo product applications,” said Kurt Workman, Owlet Chief Executive Officer.
“Our Q1 inventory sell-in was sequentially muted as we continue to partner with retailers to support sell-through inventories of Dream Sock; however, it is important to note that consumer support for the Dream Sock remains strong, as parents everywhere appreciate the peace of mind Owlet offers. In fact, parents continue to rate the Dream Sock as one of the best and most trusted wellness devices in the category. Looking ahead, we do see signs of improving sell-in to retailers resuming a growth trajectory, as healthy consumer purchasing activity depletes retailer inventory on hand. Our focused strategy is beginning to generate the results we want to drive for the health of our business, establish our trajectory for profitability later this year and achieve regulatory clearances of our products.”
Financial Results for the First Quarter Ended March 31, 2023
Revenues for the first quarter of 2023 were approximately
Cost of revenues for the first quarter of 2023 was approximately
Operating expenses were approximately
Operating loss and net loss were approximately
Adjusted EBITDA loss was approximately
Net loss per share was (
Financial Outlook
The Company will speak to its financial outlook as part of the business update provided during Owlet’s conference call on May 11, 2023 at 4:30 p.m. ET. Conference call details are provided below and on the Company’s Investor Relations website at www.investors.owletcare.com.
Cautionary Note Regarding Forward-Looking Statements and Projections
This release contains certain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Generally, forward-looking statements include the words “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements.
Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the
All future written and oral forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, Owlet operates in an evolving environment. In addition to the factors described above, new risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet.
Except as required by federal securities laws, the Company assumes no obligation to update any forward-looking statements after the date of this release, whether as a result of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
Disclosure Regarding Non-GAAP Financial Measures
In addition to the financial measures presented in this release in accordance with
The Company uses such non-GAAP financial measures as internal measures of business operating performance and as performance measures for benchmarking against the Company’s peers and competitors. The Company believes its presentation of EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share provide a meaningful perspective of the underlying operating performance of our current business and enables investors to better understand and evaluate its historical and prospective operating performance. The Company believes that these non-GAAP financial measures are important supplemental measures of operating performance because they exclude items that vary from period to period without correlation to the Company’s core operating performance and highlight trends in its business that may not otherwise be apparent when relying solely on GAAP financial measures. Due to the nature of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of the Company’s future operating performance. The Company believes investors, analysts and other interested parties use EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of the Company’s operating performance in addition to the Company’s performance based on GAAP results.
The Company’s non-GAAP financial measures should not be considered as an alternative to net loss or net loss per share as a measure of financial performance or any other performance measure derived in accordance with GAAP, and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. EBITDA is defined as net loss adjusted for income tax provision, interest expense, interest expense from contingent beneficial conversion feature, interest income, and depreciation and amortization. Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, interest expense from contingent beneficial conversion feature, interest income, depreciation and amortization, restructuring costs, warrant liability adjustments, gain on loan forgiveness, stock-based compensation, transaction costs and loss on extinguishment of debt. Adjusted net loss is defined as net loss adjusted for interest expense from contingent beneficial conversion feature, restructuring costs, warrant liability adjustments, gain on loan forgiveness, stock-based compensation, transaction costs and loss on extinguishment of debt. Adjusted net loss per share is defined as adjusted net loss divided by weighted-average shares of common stock.
EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share are not recognized terms under GAAP, and the Company’s presentation of these non-GAAP financial measures does not replace the presentation of the Company’s financial results in accordance with GAAP. Because all companies do not use EBITDA, adjusted EBITDA, adjusted net loss and adjusted net loss per share (and similarly titled financial measures) in the same way, those measures as used by other companies may not be consistent with the way the Company calculates such measures. The non-GAAP financial measures included in this release should not be construed as substitutes for or better indicators of the Company’s performance than the most directly comparable GAAP financial measures. See the reconciliation tables that accompany this release for additional information regarding certain of the non-GAAP financial measures included herein.
Conference Call and Webcast Information
Owlet will host a conference call and audio webcast today, May 11, 2023, at 4:30 p.m. ET to discuss these results.
To access the conference call by telephone, please dial (833) 470-1428 (domestic) or +1 (929) 526-1599 (international) and reference Access Code 581944. To listen to the conference call via live audio webcast, please visit the “Events” section of Owlet’s Investor Relations website at investors.owletcare.com.
A replay of the conference call will be available by telephone by dialing (866) 813-9403 (domestic) or +44 (204) 525-0658 (international) and using Access Code 561590. The archived webcast will also be available on Owlet’s Investor Relations website mentioned above.
About Owlet, Inc.
Owlet was founded by a team of parents in 2012. Owlet’s mission is to empower parents with the right information at the right time, to give them more peace of mind and help them find more joy in the journey of parenting. Owlet’s digital parenting platform aims to give parents real-time data and insights to help parents feel calmer and more confident. Owlet believes that every parent deserves peace of mind and the opportunity to feel their well-rested best. Owlet also believes that every child deserves to live a long, happy, and healthy life, and is working to develop products to help further that belief. To learn more, visit www.owletcare.com.
| Owlet, Inc. Condensed Consolidated Balance Sheets - Preliminary, Unaudited1 (in millions) |
||||||
| Assets | ######## | 31-Dec-22 | ||||
| Current assets: | ||||||
| Cash and cash equivalents | $ |
24.80 |
$ |
11.20 |
||
| Accounts receivable |
|
15.4 |
|
16 |
||
| Inventory |
|
14.7 |
|
18.5 |
||
| Prepaid expenses and other current assets |
|
5 |
|
5.6 |
||
| Total current assets |
|
59.9 |
|
51.3 |
||
| Property and equipment, net |
|
0.8 |
|
1.1 |
||
| Right of use assets, net |
|
1.9 |
|
2.3 |
||
| Intangible assets, net |
|
2.3 |
|
2.3 |
||
| Other assets |
|
1 |
|
1.2 |
||
| Total assets | $ |
65.90 |
$ |
58.10 |
||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ |
30.80 |
$ |
30.40 |
||
| Accrued and other expenses |
|
14 |
|
20 |
||
| Current portion of deferred revenues |
|
1 |
|
1.1 |
||
| Line of credit |
|
0 |
|
4.7 |
||
| Current portion of long-term debt |
|
4.8 |
|
10.4 |
||
| Total current liabilities |
|
50.7 |
|
66.6 |
||
| Long-term debt, net |
|
3.5 |
|
— |
||
| Noncurrent lease liabilities |
|
0.7 |
|
1.2 |
||
| Common stock warrant liability |
|
24.9 |
|
0.7 |
||
| Other long-term liabilities |
|
2 |
|
0.3 |
||
| Total liabilities |
|
81.9 |
|
68.7 |
||
| Total mezzanine equity |
|
4.5 |
|
— |
||
| Total stockholders’ equity |
|
-20.5 |
|
-10.6 |
||
| Total liabilities and stockholders’ equity | $ |
65.90 |
$ |
58.10 |
||
| 1 Amounts may not sum due to rounding | ||||||
| Owlet, Inc. Condensed Consolidated Statements of Cash Flows - Preliminary, Unaudited1 (in millions) |
|||
| For the Three Months Ended March 31, | |||
2023 |
2022 |
||
| Net cash used in operating activities | -9.4 |
-27.4 |
|
| Net cash used in investing activities | — |
-0.7 |
|
| Net cash provided by financing activities | 22.9 |
1.8 |
|
| Net change in cash and cash equivalents | 13.5 |
-26.3 |
|
| 1 Amounts may not sum due to rounding | |||
| Owlet, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss - Preliminary, Unaudited1 (in millions, except share and per share amounts) |
|||||||
| For the Three Months Ended March 31, | |||||||
|
2023 |
|
|
2022 |
|
||
| Revenues | $ |
10.70 |
|
$ |
21.50 |
|
|
| Cost of revenues |
|
6.6 |
|
|
12.8 |
|
|
| Gross profit |
|
4.2 |
|
|
8.8 |
|
|
| Operating expenses: | |||||||
| General and administrative |
|
8.9 |
|
|
10.3 |
|
|
| Sales and marketing |
|
3.4 |
|
|
11.6 |
|
|
| Research and development |
|
2.9 |
|
|
8.5 |
|
|
| Total operating expenses |
|
15.1 |
|
|
30.5 |
|
|
| Operating loss |
|
-11 |
|
|
-21.7 |
|
|
| Other income (expense): | |||||||
| Interest expense, net |
|
-2.8 |
|
|
-0.2 |
|
|
| Common stock warrant liability adjustment |
|
1.9 |
|
|
-6.9 |
|
|
| Other income (expense), net |
|
— |
|
|
— |
|
|
| Total other income (expense), net |
|
-0.9 |
|
|
-7.1 |
|
|
| Loss before income tax provision |
|
-11.9 |
|
|
-28.8 |
|
|
| Income tax provision |
|
— |
|
|
— |
|
|
| Net loss and comprehensive loss | $ |
(11.9 |
) |
$ |
(28.8 |
) |
|
| Deemed dividend attributable to accretion on Series A convertible preferred stock | $ |
(0.7 |
) |
$ |
— |
|
|
| Net loss attributable to common stockholders | $ |
(12.5 |
) |
$ |
(28.8 |
) |
|
| Net loss per share attributable to common stockholders, basic and diluted | $ |
(0.11 |
) |
$ |
(0.26 |
) |
|
| Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted | ######## | ######## | |||||
| 1 Amounts may not sum due to rounding | |||||||
| Owlet, Inc. Reconciliation of GAAP to Non-GAAP Measures - Preliminary, Unaudited1 (in millions) |
||||||||
| For the Three Months Ended March 31, | ||||||||
|
2023 |
|
|
2022 |
|
|||
| Net loss | $ |
(11.9 |
) |
$ |
(28.8 |
) |
||
| Income tax provision |
|
— |
|
|
— |
|
||
| Interest expense, net |
|
2.8 |
|
|
0.2 |
|
||
| Depreciation and amortization |
|
0.3 |
|
|
0.3 |
|
||
| EBITDA | $ |
(8.8 |
) |
$ |
(28.2 |
) |
||
| Common stock warrant liability adjustment |
|
-1.9 |
|
|
6.9 |
|
||
| Stock-based compensation |
|
2.8 |
|
|
3.3 |
|
||
| Transaction costs |
|
2.1 |
|
|
— |
|
||
| Adjusted EBITDA | $ |
(5.8 |
) |
$ |
(18.0 |
) |
||
| 1 Amounts may not sum due to rounding | ||||||||
| Owlet, Inc. Reconciliation of GAAP to Non-GAAP Measures - Preliminary, Unaudited1 (in millions, except share and per share amounts) |
||||||||
| For the Three Months Ended March 31, | ||||||||
|
2023 |
|
|
2022 |
|
|||
| Net loss | $ |
(11.9 |
) |
$ |
(28.8 |
) |
||
| Non-GAAP adjustments: | ||||||||
| Common stock warrant liability adjustment |
|
-1.9 |
|
|
6.9 |
|
||
| Stock-based compensation |
|
2.8 |
|
|
3.3 |
|
||
| Transaction costs |
|
2.1 |
|
|
— |
|
||
| Adjusted net loss | $ |
(8.9 |
) |
$ |
(18.6 |
) |
||
| Net loss per share attributable to common stockholders | $ |
(0.11 |
) |
$ |
(0.26 |
) |
||
| Adjusted net loss per share attributable to common stockholders | $ |
(0.08 |
) |
$ |
(0.17 |
) |
||
| Weighted average number of shares outstanding | ######## | ######## | ||||||
| 1 Amounts may not sum due to rounding | ||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005804/en/
Investors and Media
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: mike.cavanaugh@westwicke.com
Source: Owlet, Inc.
